Why Is AT&T Stock Dropping?
The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…
Buy
75
MDT Quote, Financials, Valuation and Earnings
Last price:
$88.08
Seasonality move
:
2.47%
Day range:
$87.05 - $88.63
52-week range:
$75.96 - $92.68
Dividend yield:
3.17%
P/E ratio:
26.94x
P/S ratio:
3.50x
P/B ratio:
2.33x
Volume:
9.6M
Avg. volume:
6.7M
1-year change:
2.36%
Market cap:
$112.9B
Revenue:
$32.4B
EPS (TTM):
$3.27
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MDT
Medtronic PLC
|
$8.3B | $1.25 | 2.95% | 37.36% | $95.05 |
|
ABT
Abbott Laboratories
|
$11B | $1.34 | 6.82% | 59.57% | $130.62 |
|
BSX
Boston Scientific
|
$4.4B | $0.66 | 15.3% | 94.72% | $100.78 |
|
NARI
Inari Medical
|
$160.6M | $0.01 | 21.63% | -100% | $74.12 |
|
NVRO
Nevro
|
$101.3M | -$0.76 | -13.9% | -214.67% | $5.60 |
|
TMDX
TransMedics Group
|
$109.5M | $0.15 | 34.89% | 26.33% | $102.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MDT
Medtronic PLC
|
$88.08 | $95.05 | $112.9B | 26.94x | $0.70 | 3.17% | 3.50x |
|
ABT
Abbott Laboratories
|
$113.48 | $130.62 | $196.8B | 34.49x | $0.59 | 1.97% | 4.81x |
|
BSX
Boston Scientific
|
$98.66 | $100.78 | $145.4B | 81.54x | $0.00 | 0% | 9.19x |
|
NARI
Inari Medical
|
$79.55 | $74.12 | $4.7B | -- | $0.00 | 0% | 8.03x |
|
NVRO
Nevro
|
$4.57 | $5.60 | $171.2M | -- | $0.00 | 0% | 0.40x |
|
TMDX
TransMedics Group
|
$57.20 | $102.00 | $1.9B | 60.85x | $0.00 | 0% | 4.93x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MDT
Medtronic PLC
|
36.83% | 0.589 | 24.65% | 1.17x |
|
ABT
Abbott Laboratories
|
27.35% | 0.781 | 8.05% | 1.14x |
|
BSX
Boston Scientific
|
34.45% | 0.507 | 8.79% | 0.85x |
|
NARI
Inari Medical
|
-- | 1.511 | -- | 1.32x |
|
NVRO
Nevro
|
44.82% | 0.569 | 106.2% | 3.64x |
|
TMDX
TransMedics Group
|
70.78% | 2.389 | 9.65% | 7.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MDT
Medtronic PLC
|
$5.5B | $1.6B | 5.61% | 8.54% | 21.04% | $554M |
|
ABT
Abbott Laboratories
|
$5.9B | $1.9B | 10.69% | 14.78% | 19.58% | $2.1B |
|
BSX
Boston Scientific
|
$2.9B | $718M | 5.95% | 8.91% | 17.77% | $698M |
|
NARI
Inari Medical
|
$133.5M | -$6.7M | -17.68% | -17.68% | -8.21% | -$995K |
|
NVRO
Nevro
|
$64.6M | -$15.2M | -14.09% | -24.66% | -8.31% | $161K |
|
TMDX
TransMedics Group
|
$60.8M | $3.9M | 4.86% | 19.83% | 7.23% | -$41.3M |
Medtronic PLC vs. Competitors
-
Which has Higher Returns MDT or ABT?
Abbott Laboratories has a net margin of 15.11% compared to Medtronic PLC's net margin of 15.48%. Medtronic PLC's return on equity of 8.54% beat Abbott Laboratories's return on equity of 14.78%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC64.94% $0.99 $77B ABTAbbott Laboratories55.83% $0.94 $55B -
What do Analysts Say About MDT or ABT?
Medtronic PLC has a consensus price target of $95.05, signalling upside risk potential of 7.91%. On the other hand Abbott Laboratories has an analysts' consensus of $130.62 which suggests that it could grow by 15.11%. Given that Abbott Laboratories has higher upside potential than Medtronic PLC, analysts believe Abbott Laboratories is more attractive than Medtronic PLC.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC10 15 1 ABTAbbott Laboratories13 6 0 -
Is MDT or ABT More Risky?
Medtronic PLC has a beta of 0.828, which suggesting that the stock is 17.239% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.734, suggesting its less volatile than the S&P 500 by 26.571%.
-
Which is a Better Dividend Stock MDT or ABT?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.17%. Abbott Laboratories offers a yield of 1.97% to investors and pays a quarterly dividend of $0.59 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Abbott Laboratories pays out 62.14% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or ABT?
Medtronic PLC quarterly revenues are $8.4B, which are smaller than Abbott Laboratories quarterly revenues of $10.6B. Medtronic PLC's net income of $1.3B is lower than Abbott Laboratories's net income of $1.6B. Notably, Medtronic PLC's price-to-earnings ratio is 26.94x while Abbott Laboratories's PE ratio is 34.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.50x versus 4.81x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.50x 26.94x $8.4B $1.3B ABTAbbott Laboratories4.81x 34.49x $10.6B $1.6B
-
Which has Higher Returns MDT or BSX?
Boston Scientific has a net margin of 15.11% compared to Medtronic PLC's net margin of 11.12%. Medtronic PLC's return on equity of 8.54% beat Boston Scientific's return on equity of 8.91%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC64.94% $0.99 $77B BSXBoston Scientific68.83% $0.32 $31.8B -
What do Analysts Say About MDT or BSX?
Medtronic PLC has a consensus price target of $95.05, signalling upside risk potential of 7.91%. On the other hand Boston Scientific has an analysts' consensus of $100.78 which suggests that it could grow by 2.15%. Given that Medtronic PLC has higher upside potential than Boston Scientific, analysts believe Medtronic PLC is more attractive than Boston Scientific.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC10 15 1 BSXBoston Scientific22 4 0 -
Is MDT or BSX More Risky?
Medtronic PLC has a beta of 0.828, which suggesting that the stock is 17.239% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.800, suggesting its less volatile than the S&P 500 by 20.007%.
-
Which is a Better Dividend Stock MDT or BSX?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.17%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or BSX?
Medtronic PLC quarterly revenues are $8.4B, which are larger than Boston Scientific quarterly revenues of $4.2B. Medtronic PLC's net income of $1.3B is higher than Boston Scientific's net income of $468M. Notably, Medtronic PLC's price-to-earnings ratio is 26.94x while Boston Scientific's PE ratio is 81.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.50x versus 9.19x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.50x 26.94x $8.4B $1.3B BSXBoston Scientific9.19x 81.54x $4.2B $468M
-
Which has Higher Returns MDT or NARI?
Inari Medical has a net margin of 15.11% compared to Medtronic PLC's net margin of -11.97%. Medtronic PLC's return on equity of 8.54% beat Inari Medical's return on equity of -17.68%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC64.94% $0.99 $77B NARIInari Medical87.06% -$0.31 $434.8M -
What do Analysts Say About MDT or NARI?
Medtronic PLC has a consensus price target of $95.05, signalling upside risk potential of 7.91%. On the other hand Inari Medical has an analysts' consensus of $74.12 which suggests that it could fall by -6.83%. Given that Medtronic PLC has higher upside potential than Inari Medical, analysts believe Medtronic PLC is more attractive than Inari Medical.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC10 15 1 NARIInari Medical0 13 0 -
Is MDT or NARI More Risky?
Medtronic PLC has a beta of 0.828, which suggesting that the stock is 17.239% less volatile than S&P 500. In comparison Inari Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MDT or NARI?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.17%. Inari Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Inari Medical pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or NARI?
Medtronic PLC quarterly revenues are $8.4B, which are larger than Inari Medical quarterly revenues of $153.4M. Medtronic PLC's net income of $1.3B is higher than Inari Medical's net income of -$18.4M. Notably, Medtronic PLC's price-to-earnings ratio is 26.94x while Inari Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.50x versus 8.03x for Inari Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.50x 26.94x $8.4B $1.3B NARIInari Medical8.03x -- $153.4M -$18.4M
-
Which has Higher Returns MDT or NVRO?
Nevro has a net margin of 15.11% compared to Medtronic PLC's net margin of -15.83%. Medtronic PLC's return on equity of 8.54% beat Nevro's return on equity of -24.66%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC64.94% $0.99 $77B NVRONevro66.67% -$0.41 $495.9M -
What do Analysts Say About MDT or NVRO?
Medtronic PLC has a consensus price target of $95.05, signalling upside risk potential of 7.91%. On the other hand Nevro has an analysts' consensus of $5.60 which suggests that it could grow by 22.54%. Given that Nevro has higher upside potential than Medtronic PLC, analysts believe Nevro is more attractive than Medtronic PLC.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC10 15 1 NVRONevro0 11 2 -
Is MDT or NVRO More Risky?
Medtronic PLC has a beta of 0.828, which suggesting that the stock is 17.239% less volatile than S&P 500. In comparison Nevro has a beta of 0.859, suggesting its less volatile than the S&P 500 by 14.064%.
-
Which is a Better Dividend Stock MDT or NVRO?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.17%. Nevro offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Nevro pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or NVRO?
Medtronic PLC quarterly revenues are $8.4B, which are larger than Nevro quarterly revenues of $96.9M. Medtronic PLC's net income of $1.3B is higher than Nevro's net income of -$15.3M. Notably, Medtronic PLC's price-to-earnings ratio is 26.94x while Nevro's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.50x versus 0.40x for Nevro. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.50x 26.94x $8.4B $1.3B NVRONevro0.40x -- $96.9M -$15.3M
-
Which has Higher Returns MDT or TMDX?
TransMedics Group has a net margin of 15.11% compared to Medtronic PLC's net margin of 3.88%. Medtronic PLC's return on equity of 8.54% beat TransMedics Group's return on equity of 19.83%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC64.94% $0.99 $77B TMDXTransMedics Group55.94% $0.12 $718.5M -
What do Analysts Say About MDT or TMDX?
Medtronic PLC has a consensus price target of $95.05, signalling upside risk potential of 7.91%. On the other hand TransMedics Group has an analysts' consensus of $102.00 which suggests that it could grow by 78.32%. Given that TransMedics Group has higher upside potential than Medtronic PLC, analysts believe TransMedics Group is more attractive than Medtronic PLC.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC10 15 1 TMDXTransMedics Group5 3 0 -
Is MDT or TMDX More Risky?
Medtronic PLC has a beta of 0.828, which suggesting that the stock is 17.239% less volatile than S&P 500. In comparison TransMedics Group has a beta of 2.124, suggesting its more volatile than the S&P 500 by 112.447%.
-
Which is a Better Dividend Stock MDT or TMDX?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.17%. TransMedics Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. TransMedics Group pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or TMDX?
Medtronic PLC quarterly revenues are $8.4B, which are larger than TransMedics Group quarterly revenues of $108.8M. Medtronic PLC's net income of $1.3B is higher than TransMedics Group's net income of $4.2M. Notably, Medtronic PLC's price-to-earnings ratio is 26.94x while TransMedics Group's PE ratio is 60.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.50x versus 4.93x for TransMedics Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.50x 26.94x $8.4B $1.3B TMDXTransMedics Group4.93x 60.85x $108.8M $4.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is American Express Stock Going Lower?
American Express Company (NYSE:AXP) has long been a Buffett favorite…
Cigna vs Costco Stock: Which Is Best?
Cigna and Costco don’t usually go hand in hand but…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
QMCO alert for Jan 18
Quantum [QMCO] is down 15.61% over the past day.
Buy
51
QRVO alert for Jan 18
Qorvo [QRVO] is up 14.47% over the past day.
Sell
31
ATEX alert for Jan 18
Anterix [ATEX] is up 11.14% over the past day.
